$1.20
-0.17 (-12.41%)
Open$1.35
Previous Close$1.37
Day High$1.35
Day Low$1.20
52W High$434.40
52W Low—
Volume—
Avg Volume60.9K
Market Cap1.95M
P/E Ratio0.00
EPS$149.76
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,962.5% upside
Current
$1.20
$1.20
Target
$36.75
$36.75
$26.33
$36.75 avg
$40.94
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 40.60M | 42.46M | 39.37M |
| Net Income | -1,409,045 | -1,565,662 | -1,719,749 |
| Profit Margin | -3.5% | -3.7% | -4.4% |
| EBITDA | -2,559,719 | -2,552,246 | -2,827,370 |
| Free Cash Flow | -1,137,405 | -963,691 | -1,418,550 |
| Rev Growth | +15.5% | -1.3% | +12.3% |
| Debt/Equity | 0.48 | 0.77 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |